Discrepancies between histology and serology for the diagnosis of coeliac disease (1)
Editor -Sweis and colleagues showed discrepancies between histology and serology in the diagnosis of coeliac disease (CD) (Clin Med August 2009 pp 346-8), and suggest we reduce our reliance on serology testing in diagnosing and excluding CD. However, we feel there are major reasons to reconsider this.
The numbers reported here must be interpreted carefully: 10 out of 26 CD patients who received serologic testing were seronegative. This 38.5% occurrence of seronegative CD is misleading. In the spirit of Bayes theorem, the more common the condition we are testing, the greater the percentage of false negative results. 1 In this case, all 26 patients were selected due to the diagnosis of CD, meaning the prevalence in this group was already 100%. Therefore, this group is bound to have a high number of false negative tests. The authors correctly state that a small number of cases of CD will be missed by relying on serology alone, but the true prevalence is unknown, and this number is likely to be much lower than 38.5%.
In addition, the predictive value of using an ELISA-based method to detect tissue transglutaminase autoantibody (tTG) remains open to discussion. There are currently numerous tTG assays available, all with varying performances. The International tTG Workshop for CD performed head-to-head comparisons of various commercial and laboratory-based tTG assays. For this workshop, assays reported sensitivities ranging from 82% to 93%, underscoring the marked variability in assay performance. 2 Given these findings, the lack of positive serology in a proportion of their biopsy-proven coeliacs could be assay dependent.
Finally, even though intestinal biopsy is the gold standard method to diagnose CD, it is not without its short comings. The sensitivity of histology is largely dependent on the site and number of biopsy samples taken. 3, 4 Negative histology often excludes a diagnosis of CD. However, a proportion of these patients have CD-like gastrointestinal symptoms, which might be attributed to the subtle changes seen in microscopic enteritis that could go undetected. 5 In all, we agree that it is important not to rely on serology alone for the diagnosis of CD, but to allow serology to increase or decrease your estimation of risk of disease. However, considering the lifelong implications of a diagnosis of CD, one should still maintain a degree of suspicion and also take great care in interpreting villous atrophy in the absence of autoantibodies in any patient. What has also emerged is that the agerelated differences documented in the clinical and histological stigmata of CD, have, as a corollary, a correlation between TGAA levels and degree of villous atrophy. This was shown in a study where severe villous atrophy (Marsh IIIB and IIIC) was significantly (pϽ0.0001) more prevalent in children than in adults. In that study, a significant correlation was also established between IgA TGAA titres and age (Pearson coefficientϭ0.524; pϽ0.001), and also between IgA TGAA titres and degree of villous atrophy (Spearman rhoϭ0.59; pϽ0.001). 4 Accordingly, given the fact that concordance between histology and serology depends, not only on the performance and methodology of the laboratory performing the serological tests, but also on patient characteristics, histology should continue to be the 'gold standard' for diagnosis of CD.
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In response
We would like to thank the respondents for their helpful insights and comments which offer several plausible explanations for the discrepancy we observed between serological and histological testing for coeliac disease (CD). The ELISA-based IgA anti-tissue transglutaminase (anti-tTG) assay used at Medway Hospital is typical of that used at many peripheral centres. Although an antibody radiobinding assay for measuring IgA antibodies to human tissue transglutaminase has been shown to achieve a sensitivity and specificity at least equivalent to endomysial antibody, 1 it is not readily available. It is therefore common practice to combine serological testing in order to improve sensitivity and specificity. 2 The positive and negative predictive value of combining IgA anti-tTG antibodies and IgA anti-endomysial antibodies has been reported to be over 95%. 3 A multicentre European study showed that out of 126 biopsy-confirmed cases with CD, eight (6.4%) had negative combined IgA anti-tTG (ELISA-based) and IgA anti-endomysial antibodies. 4 We accept that the IgA and IgG anti-gliadin antibody assay is no longer used in most centres due to reduced sensitivity and specificity, and serological testing at Medway hospital has since been changed to IgA and IgG anti-endomysial antbody and IgA and IgG anti-tissue transglutaminase. Furthermore, although none of the patients were known to be on a formal gluten free diet, it is possible that some may have reduced their gluten intake prior to serology testing.
We fully accept that our false negative rate for serology should be interpreted with caution and because of the small numbers, may overestimate the magnitude of the problem. Never the less, it would be surprising if this finding was unique to our hospital. There is often a long delay in diagnosis ranging from 4.9 to 11 years, 5, 6 as illustrated by our case study and the increasing reliance on noninvasive testing means that patients will remain undiagnosed. What is clear is that we all agree that it is important for physicians to be aware of the more protean presentations of CD, the limitations of serology and the importance of a duodenal biopsy in making the diagnosis of CD.
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